-
Albuterol
- Short acting beta2 adrenergic agonists
- Bronchodilation
- Use for rescue relief from bronchoconstriction
-
Salmeterol
- Long acting beta2 adrenergic agonists
- Bronchodilation
- Most effective with inhaled glucocorticoids
- Should not be used as monotherapy because of a lack of persistent anti-inflammatory effects
-
Fluticasone
- Glucocorticoid - inhalant
- Anti-inflammatory
- Inhibition of leukotriene/prostaglandin synthesis
- Regulation of inflammatory mediators
- Regulation of norepinephrine and histamine
-
Prednisone
- Glucocorticoid - systemic
- **use 1-2 weeks, chronic = life-threatening
- Anti-inflammatory
- Inhibition of leukotriene/prostaglandin synthesis
- Regulation of inflammatory mediators
- Regulation of norepinephrine and histamine
-
Zafirlukast
Leukotriene blocker, receptor antagonist
-
Zileuton
Leukotriene blockers, synthesis inhibitor
-
Ipratropium
- Antimuscarinic, muscarinic antagonist
- Competitively inhibit bronchoconstriction produced by acetylcholine at muscarinic receptors
- When co-administered with a beta agonist, leads to 10-15% further improvement
-
Theophylline
- Methylxanthine
- antagonist at adenosine receptors
- inhibitor of phosphodiesterase
-
Omalizumab
- Anti-IgE
- antibody that binds to IgE
- omalizumab bound IgE cannot activate mast cells
- will not reverse bronchoconstriction
|
|